At Extreme Investor Network, we strive to bring you the latest and most valuable information in the world of business news. Today, we are excited to share an update on Eli Lilly’s highly popular weight loss injection, Zepbound, and diabetes drug, Mounjaro.
According to the U.S. Food and Drug Administration’s drug shortage database, all doses of Zepbound and Mounjaro are now available in the U.S. This news comes after a previous update noted that some doses of these treatments were still in short supply. Demand for weight loss and diabetes drugs has been outpacing supply, leading Eli Lilly and its rival, Novo Nordisk, to invest billions to increase manufacturing capabilities.
Eli Lilly CEO, David Ricks, recently told Bloomberg that the shortages of Mounjaro and Zepbound would end “very soon.” This statement was followed by the FDA’s update confirming the availability of all doses of Novo Nordisk’s diabetes injection, Ozempic, in the U.S. However, some doses of Novo Nordisk’s weight loss drug, Wegovy, still have limited supply.
It is encouraging to see these pharmaceutical companies working to address the supply shortages of vital medications. Stay tuned to Extreme Investor Network for more updates on the latest developments in the business world. Don’t miss out on valuable insights – join us today!